Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Seniors have a 61% higher risk of stroke if their parents divorced when they were children or teenagers, researchers reported in a study published Wednesday in the journal PLOS One.

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Although depression most often arises in response to some kind of defeat, depression can seem to arise out of the blue, for no obvious reason. It may even arise when life appears to be going ...

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.